StockData
TAO Synergies Inc. logo

TAO Synergies Inc. (TAOX) company profile

TAOXNasdaqFinance ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30117% above fair value
$1.87+0.01 (+0.54%)

Close on Nov 17, 2026Market cap $13.99MP/E –Yield –

About TAO Synergies

Finance Services, SIC 6199

TAO Synergies Inc., formerly known as Synaptogenix, Inc., is a clinical-stage biopharmaceutical company that also operates a cryptocurrency treasury and media initiative. The company primarily develops its lead drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease and other neurodegenerative conditions such as Fragile X syndrome. Additionally, it operates a long-only cryptocurrency treasury strategy focused on accumulating and staking TAO tokens on the Bittensor decentralized artificial intelligence network to generate revenue. The company also produces news, insights, and podcasts covering the Bittensor ecosystem through its TAO Daily platform. Because its biopharmaceutical candidates remain in development, its target beneficiaries include patients with cognitive disorders, alongside participants and investors in the decentralized machine learning sector.

The company's operations originate in the United States, conducting research collaborations and clinical trials with domestic institutions such as Nemours Children's Hospital and the Cleveland Clinic. It maintains a corporate subsidiary, TAOX Florida Inc., to facilitate its digital asset treasury activities. The provided text does not state the company's headquarters location.

Summary of the business section of TAO Synergies's latest annual report, written by StockData.

Company profile

Company

Legal name
TAO Synergies Inc.
Founded
2012
Headquarters
New York, NY
Address
1185 Avenue Of The Americas, 3rd Floor 10036
Phone
(973) 242-0005
Employees
4, Dec 31, 2025
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Stephano Slack LLC, Wayne, Pennsylvania

Stock & identifiers

Ticker
TAOX
Former tickers
SNPX until Jul 17, 2025
Exchange
Nasdaq
IPO date
Dec 8, 2020
Shares outstanding
7M, Aug 13, 2026
Public float
$19.44M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Apr 5, 2024; 1-for-4 reverse, May 19, 2021
SEC CIK
1571934
CUSIP
87167T300
ISIN
US87167T3005
FIGI
BBG00YG4Q0S0
Share class FIGI
BBG00YG4Q1N3
EIN
46-1585656

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joshua SilvermanExecutive Chairman, Director217,931
Alan J. TuchmanChief Medical Officer, Director3,909
Robert WeinsteinChief Financial Officer16,574
Bruce BernsteinDirector80,897
William S. SingerDirector19,566
Robert EphronDirector4,500
Jonathan SchechterDirector22,665

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOtherTotalvs. prior year
Alan J. Tuchman
former Chief Executive Officer and current CMO
$222.00K$50.00K$6.23K$278.23K-8%
Robert Weinstein
CFO, Secretary and Executive Vice President
$348.41K$100.00K$117.47K$565.88K-1%
Daniel L. Alkon
former President and CSO(3)
$300.00K$50.00K–$350.00K-7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of the date of this Annual Report on Form 10-K, we have four full-time personnel, including three executive officers and one employee who is primarily engaged in administrative activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 24, 2025Name changeName changed from Synaptogenix, Inc. to TAO Synergies Inc.
Oct 4, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 16, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 4, 2021ListingRegistration of securities on an exchange (Form 8-A)
Nov 20, 2020Name changeName changed from NEUROTROPE BIOSCIENCE, INC. to Synaptogenix, Inc.

See a number that looks wrong?